Accelerated cloning of high-efficiency production cell lines may get new protein therapeutics to the clinic sooner and reduce production costs
SAN DIEGO, Sept. 22 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live-cell analysis and manipulation systems, announced today the launch of CellXpress, powered by the Company's proprietary laser-based system LEAP(TM). The automated system brings new improvements in speed, cost and optimal clone selection for cell line development. Biopharmaceutical teams developing manufacturing cell lines for potential medicines can now reduce the time required to get to clinical testing, decrease production costs of protein therapeutics and substantially increase the number of development projects which can be processed in parallel.
CellXpress can be purchased by customers directly from Cyntellect in the U.S. and Europe and from Cyntellect's distribution partner, Summit Pharmaceuticals, in Japan.
The CellXpress system exploits high-speed imaging of living cells
combined with simultaneous laser elimination of undesired cells, leaving
behind cells that are efficiently secreting biopharmaceutical proteins. The
process is initiated by imaging thousands of cells per well to quantify the
level of protein being secreted by each cell. This unique measurement is
enabled by Cyntellect's proprietary in situ assay for capturing and
labeling secreted protein around living individual cells. The best
secreting cell is located in seconds within a pool of thousands of
candidate cells, and once located; all other undesired cells are
selectively eliminated with the laser leaving behind only the best cell.
This purification results in a verified clone that is very likely to
generate a highly secreting cell lines. The imaging and purification
processes can be repeated hundreds of times an hour to enable scanning
through millions of cells per day, often yielding h
Copyright©2008 PR Newswire.
All rights reserved